10-Q: Modular Medical Reports Increased R&D Spending Amidst FDA Submission

Sentiment:

Quarterly Report 13 February 2024 4:40 PM

Modular Medical's Q3 report shows increased research and development expenses as the company prepares for FDA clearance of its MODD1 insulin pump.

Capital raiseThe company completed a public offering in May 2023, raising $9.7 million in net proceeds.The company entered into an at-the-market (ATM) agreement for up to $6.5 million in November 2023.The company sold 153,879 shares of common stock for net proceeds of approximately $278,000 under the ATM Agreement in January 2024.The company received approximately $550,000 from the exercise of warrants in January 2024.The company's ability to continue as a going concern depends on its ability to raise additional capital.

Worse than expectedThe company's net loss increased compared to the same period last year.The company's cash balance decreased significantly, raising concerns about its short-term liquidity.The company's accumulated deficit increased, highlighting its ongoing losses.There is substantial doubt about the company's ability to continue as a going concern.

Summary

Modular Medical, Inc. reported its financial results for the quarter ended December 31, 2023, showing a net loss of $5.269 million, or $0.23 per share.
The company's research and development expenses increased significantly to $3.619 million for the quarter and $9.204 million for the nine months ended December 31, 2023, driven by employee costs, stock-based compensation, and consulting fees related to the FDA submission.
General and administrative expenses also rose to $1.650 million for the quarter and $4.006 million for the nine months ended December 31, 2023, due to increased facility costs, marketing, and professional fees.
The company's cash balance decreased to $2.047 million as of December 31, 2023, from $3.799 million at the beginning of the period.
Modular Medical completed a public offering in May 2023, raising $9.7 million in net proceeds, and entered into an at-the-market (ATM) agreement for up to $6.5 million.
The company submitted its MODD1 insulin pump for FDA 510(k) clearance in January 2024 and expects initial feedback by the end of June 2024.
There is substantial doubt about the company's ability to continue as a going concern due to ongoing losses and the need for additional capital.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges, including increased losses, decreased cash, and a going concern warning. While there are positive developments like the FDA submission, the overall sentiment is negative due to the company's financial instability.

Positives

The company successfully completed a public offering in May 2023, raising $9.7 million.
The company submitted its MODD1 insulin pump for FDA 510(k) clearance in January 2024, a key milestone.
The company has secured an ATM agreement for up to $6.5 million, providing a potential source of future funding.
The company has increased its R&D headcount to 36, indicating a focus on product development.

Negatives

The company experienced a significant net loss of $5.269 million for the quarter ended December 31, 2023.
The company's cash balance decreased to $2.047 million, raising concerns about its short-term liquidity.
The company has an accumulated deficit of $61.4 million, highlighting its ongoing losses.
There is substantial doubt about the company's ability to continue as a going concern.
Research and development expenses increased significantly, indicating high cash burn.
General and administrative expenses also increased, adding to the company's financial strain.

Risks

The company's ability to continue as a going concern is dependent on raising additional capital.
The company may be required to curtail R&D initiatives and reduce costs if it cannot secure additional funding.
The company faces risks related to the commercialization of its product, competing technologies, and market developments.
The company is subject to economic disruptions, including the impact of COVID-19, inflation, and rising interest rates.
The company's future capital requirements are uncertain and depend on various factors.
The company may be unable to access capital markets in the future, or may only be able to do so on unfavorable terms.

Future Outlook

The company expects research and development expenses to decrease for the remainder of fiscal 2024 after the FDA submission. The company anticipates initial feedback from the FDA on its 510(k) submission during the quarter ending June 30, 2024. The company's ability to continue as a going concern depends on its ability to raise additional capital.

Management Comments

Management believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the company has recorded a full valuation allowance.
Management concluded that, as of December 31, 2023, the company's disclosure controls and procedures were effective.
Management expects research and development expenses to decrease for the remainder of fiscal 2024.
Management expects general and administrative expenses to decrease for the remainder of fiscal 2024.

Industry Context

The company operates in the medical device industry, specifically focusing on insulin pump technology for diabetes management. The market is competitive, with established players and emerging technologies. The company's success depends on its ability to obtain regulatory approvals, commercialize its product, and compete effectively in the market.

Comparison to Industry Standards

The company's R&D spending as a percentage of total expenses is high, which is typical for a development-stage medical device company. This is comparable to companies like Insulet (PODD) and Tandem Diabetes Care (TNDM) in their early stages.
The company's net loss and negative cash flow are also typical for a pre-revenue company in this sector. However, the level of cash burn and the going concern warning are concerning and require close monitoring.
The company's reliance on equity financing is common in the industry, but the need for additional capital raises questions about its long-term financial sustainability.
The company's focus on a two-part patch pump is a differentiating factor, but it needs to demonstrate clinical efficacy and market acceptance to compete with established players.
Compared to larger, more established companies, Modular Medical is at a higher risk of failure due to its limited resources and dependence on successful product development and commercialization.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Increase in shares reserved for issuance	The company's stockholders approved an increase in the number of shares reserved for issuance under the 2017 Equity Incentive Plan by 3,000,000 shares.	February 13, 2024	This will allow the company to issue more stock options and restricted stock units to employees, directors, and consultants.
Increase in authorized shares	The company's stockholders approved an increase in the authorized shares of common stock to 100,000,000.	February 13, 2024	This will allow the company to issue more shares of common stock in the future.

Stakeholder Impact

Shareholders face significant risk due to the company's financial instability and the potential for dilution from future capital raises.
Employees may be impacted by potential cost-cutting measures, including reduced headcount.
Customers may be affected by delays in product development and commercialization.
Suppliers and creditors face increased risk due to the company's financial challenges.

Next Steps

The company expects initial feedback from the FDA on its 510(k) submission during the quarter ending June 30, 2024.
The company will need to raise additional capital to continue operations.
The company will continue to develop and commercialize its MODD1 insulin pump.

Key Dates

Date	Description
October 1998	Modular Medical, Inc. was incorporated in Nevada under the name Bear Lake Recreation, Inc.
June 2017	The company changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.
February 2022	The company completed a public offering of its equity securities and began trading on the Nasdaq Capital Market.
February 1, 2023	The 48-month lease term for the Thornmint Road facility commenced.
May 15, 2023	The company entered into an underwriting agreement for a public offering.
May 18, 2023	The 2023 public offering closed.
May 25, 2023	The underwriter exercised its over-allotment option in full.
June 30, 2023	The 39-month lease term for the W. Bernardo Drive facility expired.
November 22, 2023	The company entered into an ATM agreement with Leerink Partners LLC.
December 29, 2023	The company issued shares of unregistered common stock to non-employee directors.
December 31, 2023	End of the reporting period for the quarterly report.
January 2024	The company submitted its MODD1 insulin pump for FDA 510(k) clearance and sold shares under the ATM agreement.
February 9, 2024	The number of outstanding shares of the company's common stock was 21,899,058.
February 13, 2024	The company's stockholders approved increases in the number of shares reserved for issuance under the Plan and the authorized shares of common stock.

Keywords

insulin pump, medical device, FDA clearance, research and development, capital raise, MODD1, diabetes, financial results, going concern, stock offering

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.